Questions we are asked every week

It comes down to three things: financial base, timing window and whether you need primary capital. A traditional IPO is the longest (12-18 months) and most expensive, but raises capital at listing and brings an underwriter's endorsement. A reverse merger is fastest (4-8 months) but usually raises no new money, and shell quality decides whether you can uplist. A SPAC sits between the two (6-10 months): the merger is the listing with cash already in trust, at the cost of sponsor-promote dilution and redemptions. Start with the free 30-minute route diagnosis - laying the three routes side by side beats picking a route first and fixing the gaps later.

Market-practice ranges: 12-18 months for a traditional IPO, 4-8 months for a reverse merger, 6-10 months for a SPAC merger. The ranges are wide because preparation workloads differ - audit remediation, structure and controls start from different places - not because filing itself is slow. The actual timeline depends on the financial base, adviser coordination and the issuance window; after mandate we run a milestone-based reverse schedule.

Costs come in two groups: fixed costs independent of deal size (audit, US and PRC counsel, restructuring, controls, printing, initial listing fee) and costs that move with the raise (underwriting fee, roadshow and IR, annual listing fees). Route, raise size and the number of historical years can move the total by multiples, so we do not publish one headline number - pricing follows the route diagnosis, scoped by project and split into fixed and variable columns.

Nasdaq Rule 5210(l), approved by the SEC on 14 May 2026 and effective 13 June 2026, applies specifically to China-based issuers: firm-commitment IPOs must raise at least US$25 million; after a SPAC or reverse merger, the market value of unrestricted publicly held shares (MVUPHS) must be at least US$25 million; direct listings are limited to the Global Select Market; and uplisting from OTC requires one year of continuous trading on the prior market. The look-through test covers mainland China, Hong Kong and Macao. See the dedicated rule page on this site.

MVUPHS stands for Market Value of Unrestricted Publicly Held Shares: the value of shares freely tradable and held by non-affiliates. From 17 January 2026 the threshold for ordinary issuers rose from US$5 million to US$15 million; under the 2026 rules, a China-based issuer must hold at least US$25 million in MVUPHS after a SPAC or reverse merger. It decides eligibility because it measures whether a real public market will exist after listing - below the threshold, a listing is only a ticker.

An investment bank, not a headhunter. A search firm delivers a person; we deliver the listing: US IPO, reverse merger, shell transactions, SPAC and De-SPAC, SEC filing and post-listing capital raising, run end to end. CFO and listing-team build-out is one workstream inside every route, scheduled against listing milestones - it is not a standalone placement fee. The difference: a headhunter starts after you have decided to hire; we start while you are still deciding which route to take.

Four checks, all verifiable on the spot. One: complete track record - how many deals, split by IPO / SPAC / reverse merger, and whether the tickers can be found in public records. Two: where the team actually comes from - did partners do US deals at an international bank or a Big Four firm, in which role and for how many years. Three: rule detail - the 2026 Nasdaq China-issuer rules, PCAOB audit requirements, the Super 8-K audit standard; if they cannot answer, they have not done it. Four: stated boundaries - are they willing to say which markets they do not cover. Anyone who says the equivalent of industry-leading without a checkable number should be ruled out.

No conversation ends with you are not ready. The first 10-minute call ends one of two ways: we can take it, or we cannot take it yet and here is exactly what is missing. Where the gaps are fixable - audit positions, related-party cleanup, undocumented controls, retrospective option valuation - we state how long each takes, who does it, and whether closing them gets you to the target tier. We decline in one case only: when the gap between the goal and the financial base is measured in years and the timeline cannot move. Being straight about it beats taking the mandate and slipping for a year.

We contract by scope and by stage: every stage has its deliverable, acceptance test and fee written into the agreement, and a stop settles against completed stages - you never find out the cost halfway through. We do not bet on outcomes and we do not promise a successful listing; nobody can promise an SEC review conclusion or an issuance window, and anyone who does should worry you. What actually reduces risk is the front end: the 30-minute route diagnosis is free and requires no signed mandate precisely so feasibility is clear before any money moves.

The quote holds for the scope signed. It moves in only two cases, and both are confirmed in writing in advance: the scope changes (a third historical year is added, an offshore entity needs restructuring), or remediation work appears that could not have been foreseen at signing (undisclosed related-party cash flows surfacing in the audit). In either case you get a written change note with the corresponding price before any work starts - never an after-the-fact add-on.

Yes. Listing discussions are covered by confidentiality before any mandate, and we sign an NDA where you require one. The route diagnosis does not need your underlying ledgers - only the business, the target timeline and the order of magnitude of your current financial base. Redaction runs both ways: published case studies never name clients, and team profiles are released as first name plus surname initial and prior firm until an NDA is in place. In this business a loose-lipped adviser does not survive - that is our own problem, not just a service promise.

Yes, and the roles do not overlap. The bank underwrites and distributes, counsel gives legal opinions and documents, but nobody owns stitching it together and driving the schedule: who fixes the audit positions, when the structure is done, who keeps the control evidence, who answers SEC comments, how the equity story is framed before the roadshow. That orchestration normally falls to the issuer's own CFO, and most China-based companies preparing to list do not have one who can carry it. That is the seat we fill.

It depends on whether that CFO has run a full cycle: led an S-1 or F-1, carried every SEC comment round, produced the first post-listing 10-K or 20-F and SOX 404. Someone who only touched part of it will struggle at filing. The second hurdle is whether you can hire that person at all: candidates who can write SEC filings in native-level English, present to US investors and still join a private company are a very small pool - our own average from role definition to start date is 51 days. The third is time: one CFO cannot run structure, auditor coordination, controls and underwriter interface in parallel. That is a team's workload.

A written judgement: for IPO, reverse merger and SPAC, the thresholds each route sets given your current position, the market-practice timelines and cost structure, which route we would take and what to fix first. Free, no mandate required, fully confidential. If either side concludes it is not a fit, the conversation ends there - there is no sales sequence and no follow-up campaign afterwards. Whether we can take it is the only question that call needs to answer.

Language is a hard gate: the CFO must be able to write SEC filings in English, handle regulatory questions and run an English roadshow. Mandarin is not required, but a bilingual finance director is needed to work with the onshore team. Compensation usually has three parts: base salary, bonuses tied to listing milestones (filing, comment response, listing - not a bet on success), and equity (options or restricted shares, with grant-date fair value set by a 409A valuation). We publish no ranges, because level, sector and stage vary too much. The three things that most often go wrong: option pool size and dilution not modelled, vesting not tied to filing milestones, and tax plus cross-border payroll arrangements for paying a non-resident not designed up front.

Because US rules, audit and disclosure form a self-contained discipline, and depth in one market beats breadth across three. Nasdaq and NYSE listing standards, SEC filing and comment logic, PCAOB audit requirements, and what market makers and institutional investors actually want - each needs people who live in it. We do not cover Hong Kong, A-shares (including the STAR Market and ChiNext), the Beijing Stock Exchange or the NEEQ market, nor Singapore or London. When the enquiry is outside our scope we say so rather than take it and subcontract.

No - there is no relationship between them. 51cfo.team (51CFO) is a US-market investment banking team: US IPO, reverse merger, shell transactions, SPAC and De-SPAC, SEC filings and post-listing capital raising, with partners from Goldman Sachs, Morgan Stanley and the Big Four. 51cfo.com.cn is the site of the China CFO Alliance, a domestic community and industry network for finance professionals in China; it does not take on US listing mandates. Two domains, two teams, two businesses - no ownership, personnel or operational link. If you need someone to run a US listing, that is this site. If you need a domestic finance community, that is the other one.

Yes, and it is meant to be checked. The team is ten partners, with prior firms stated openly - Goldman Sachs, Morgan Stanley and other international banks, plus the Big Four. Each profile lists the firm, the function and the years. Public profiles use first name plus surname initial; full names and CVs are released under NDA, because some partners are still employed elsewhere and naming them publicly would affect their current roles. Founder: Brian Tian. Published cases never name clients, but deal type, exchange tier and publicly checkable timing are always stated so you can verify independently. The most reliable way to test a team is not the marketing copy - it is rule detail: the 2026 Nasdaq China-issuer rules, PCAOB audit requirements, the Super 8-K audit standard. Answer those and it shows the work was real.

51CFO is a service brand of CHAIN FIR CAPITAL MANAGEMENT CO., LIMITED, a New Zealand registered company: Companies Register number 8225373, NZBN 9429049664744, incorporated on 26 August 2021, registered in Auckland. All three identifiers are searchable in the public record of the New Zealand Companies Office (companiesoffice.govt.nz); the company record sits at app.companiesoffice.govt.nz/co/8225373, so you can verify it yourself without anything from us. Founder Brian Tian is also a registered director of the company, which is likewise a matter of public record.

No. OTC is an unregulated over-the-counter market with no formal financial, governance, or disclosure requirements. Nasdaq is a national securities exchange requiring strict eligibility (e.g., profitability, market value, liquidity) and ongoing SEC/Nasdaq oversight. OTC quotation does not confer listing status and cannot convert automatically—full Nasdaq application and qualification are required.

We review EDGAR filings for pending litigation, undisclosed liabilities, or regulatory violations; verify clean audit opinions and absence of going-concern qualifications; confirm management has no SEC bars and the shell has no nominee arrangements or hidden controllers. 51CFO coordinates with U.S. counsel to execute a comprehensive due diligence checklist.

Dilution primarily stems from warrants issued at IPO (exercisable into common stock), founder shares with anti-dilution features, new shares issued to target shareholders in the De-SPAC merger, and underwriters’ greenshoe option. All increase total shares outstanding, reducing ownership percentage of pre-merger SPAC shareholders.

Red Chip involves direct equity ownership: domestic entities hold offshore SPVs, which then make round-trip investments into operating entities—permitted where foreign investment is allowed. VIE relies on contractual control, used in restricted sectors. VIE carries higher regulatory and enforcement risk; Red Chip is more transparent but subject to SAFE registration and foreign exchange controls.

Yes. Foreign private issuers filing with the SEC (e.g., Form 20-F, F-1) must engage a PCAOB-registered auditor in good standing. SEC will reject submissions otherwise. 51CFO identifies and engages a qualified PCAOB-registered firm within two weeks of engagement.

US GAAP conversion usually takes 3–6 months, depending on ERP maturity, historical record quality, and auditor readiness. With IFRS or robust ERP (e.g., SAP), it may compress to 8–12 weeks; otherwise, rebuilding chart of accounts and sourcing documentation often extends it beyond 4 months. We assess this during the free diagnostic.

Begin SOX 404 internal control implementation 12–18 months pre-listing; critical process documentation and testing must be completed at least 9 months prior. SEC requires a 404(a) report in the first annual report (10-K) post-listing. Delayed preparation risks audit delays and regulatory exposure. Our SOX advisors deliver a phased roadmap post-diagnostic.

Yes. Both NASDAQ and NYSE require a qualified CFO to be appointed at the time of listing application. The CFO must have direct experience with SEC reporting, US GAAP financial statements, or SOX 404 implementation — not just domestic accounting. They must sign registration statements, participate in roadshows, and oversee post-listing disclosures.

A CFO who has served as signing officer or lead finance executive through a full NASDAQ/NYSE IPO: S-1/F-1 filing, SEC comment letter responses, underwriter due diligence, pricing/roadshow, and listing. They must also have led the first post-IPO 10-K/20-F and SOX 404 assessment. SPAC merger or reverse takeover experience alone does not qualify.

Post-listing, SEC mandates annual 10-K or 20-F, quarterly 10-Q, and timely 8-K filings for material events. SOX 404 internal control reporting is also required, alongside exchange-specific compliance (NASDAQ/NYSE). We support preparation, review, and submission to meet U.S. regulatory standards.

No. 51CFO exclusively serves the U.S. market (NASDAQ/NYSE/SEC/SPAC), including IPOs, reverse mergers, SPAC transactions, De-SPAC, and post-listing compliance & follow-on offerings. Our team comprises SEC, NASDAQ, NYSE, and top-tier investment banking professionals.

The first call is a 10-minute intake: you briefly share business model, target timeline, and current financial status; we confirm same-day feasibility. If viable, we schedule a free, confidential 30-minute diagnostic—comparing IPO, reverse merger, and SPAC paths on thresholds, timelines, and cost ranges—no commitment required.